Related Experiment Video
Updated: Apr 27, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Fear-potentiated behaviour is modulated by central amygdala angiotensin II AT1 receptors stimulation
Maria de los Angeles Marinzalda1, Pablo A Pérez1, Pascual A Gargiulo2
1Laboratory of Neuropharmacology, Institute of Biological and Technological Research (IIBYT-CONICET), National University of Córdoba, Faculty of Chemical Sciences, Catholic University of Córdoba, 5017 Córdoba, Argentina.
Abstract:
Central nucleus of the amygdala (CeA) is one of the most important regulatory centres for the emotional processes. Among the different neurotransmitter systems present in this nucleus, AT1 receptors have been also found, but their role in the generation and modulation of emotions is not fully understood. The present work evaluated the effect of intra-amygdalar injection of losartan (AT1 receptor antagonist) and angiotensin II (Ang II) in the anxiety state induced by fear-potentiated plus maze in male Wistar rats. Fear in the elevated plus maze can be potentiated by prior inescapable footshock stress. The decrease in the time spent in the open arms induced by the inescapable footshock was totally prevented by losartan (4 pmol) administration in CeA. It was also found that Ang II (48 fmol) administration decreased the time spent in the open arms in animals with or without previous footshock exposure. The locomotor activity and grooming behaviour were also evaluated. The results obtained from the different parameters analyzed allowed us to conclude that the Ang II AT1 receptors in CeA are involved in the anxiety state induced by stress in the fear-potentiated plus-maze behaviour.
Related Concept Videos
Role of Amygdala in Memory
One of the...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Action of β1 Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Hypertension II: Pathophysiology

